London, UK: 29 August 2006 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that its forthcoming phase I trial of AS1409 will enrol patients with renal cancer and melanoma. High levels of the drug’s target are found in these cancers.
